WITHDRAWN: Expression analysis of Sca-1 and its significance in lung cancers

Ahead of Print article withdrawn by publisher. The purpose of the present study was to determine the expression of Sca-1, the stem cell marker, among various lung cancers and evaluate their utility. Immunohistochemistry was done in 151 surgically resected lung cancer specimens or biopsies, including 76 cases of adenocarcinoma, 50 cases of squamous cell carcinoma, 15 cases of small cell carcinoma, 6 cases of adenosquamous cell carcinoma and 4 cases of large cell carcinoma. The results showed that 88 (58.3%) cases were Sca-1 positive. Further analysis showed that in cases of adenocarcinoma, the rate of lymph node invasion and poor differentiation level of Sca-1(+) specimens were respectively higher than those of Sca-1(-) specimens. In cases with small cell carcinoma and squamous cell carcinoma, the rates of lymph node invasion of Sca-1(+) specimens were respectively higher than those of Sca-1(-) specimens. Survival analysis showed that for patients with adenocarcinoma and small cell carcinoma, the average survival time of Sca-1(+) patients was significantly shorter than that of Sca-1(-) patients. Further mutation analysis showed that EGFR mutation rates in Sca-1 (-) adenocarcinoma patients were significantly higher than those of Sca-1 (+) patients, while p53 and KRAS mutation rates in Sca-1 (-) adenocarcinoma and squamous cell carcinoma patients were respectively lower than those of Sca-1 (+) patients. Western blots analysis showed that expression of a Src family tyrosine kinase, Fyn, was positively related with Sca-1 expression levels. These results suggested that Sca-1 expression in some human lung cancers was related with malignancy phenotype and survival time. Keywords: Sca-1 expression, stem cancer cell, lung cancer, malignancy phenotype.